Refine by
Oncologist Articles & Analysis: Older
119 articles found
Alfa Cytology has unveiled new services focused on therapeutic antibody development for bladder cancer research.Alfa Cytology, a prominent cancer research services supplier based in New York, proudly announces the launch of its comprehensive services for bladder cancer therapeutic antibody development. This initiative represents a critical advancement in pursuing effective bladder cancer ...
Breast cancer remains one of the most prevalent malignancies affecting women worldwide, necessitating innovative approaches for effective treatment and research. Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). These advancements not only enhance our understanding of the disease ...
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in the regulation of gene expression. Their ability to modulate various biological processes makes them significant players in the field of molecular biology and medicine. Among the various tools utilized in research and therapeutic applications, miRNA mimics have emerged as powerful instruments for manipulating and ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. Alfa Cytology, celebrated for its cutting-edge biotech solutions and extensive tumor research expertise, has recently introduced brain tumor drug development services, designed to empower researchers in understanding the intricacies and unique challenges associated with brain tumors. Brain tumors represent a ...
Clinical trials are the backbone of modern medicine, responsible for bringing innovative, safe, and efficient treatments to market after rigorous testing and evaluation. However, the conventional process of conducting these trials has often been long, expensive, and fraught with inefficiencies¹. The advent of predictive analytics is reshaping the landscape of clinical trials, ushering in a ...
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty. In the era of precision oncology, it has become increasingly common for patients diagnosed with cancer to undergo tumor sequencing. Identifying the mutations that make up a tumor’s genomic landscape can help guide selection of targeted therapies and inform ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹?³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and ...
Alfa Cytology, a pioneering biotech firm comprising an interdisciplinary team of scientists, bioinformaticians, and oncologists, has recently introduced its cancer diagnostic biomarker development services to advance personalized cancer treatment strategies. ...
CD BioSciences, a biotech company specializing in centrosomal study, has recently launched new services for anti-centrosome antibody development. The services help identify and track centrosomes in experiments, demonstrating the strength of anti-centrosome antibodies as a great tool for centrosome research. The centrosome is a key cellular structure that plays a crucial role in the organization ...
As exploration progresses, the hope is that cancer vaccines will become a standard part of the oncologist’s toolkit, transforming the landscape of cancer treatment and offering new hope to patients worldwide. ...
In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow. ...
Brain tumors can be broadly categorized into primary and secondary (or metastatic) tumors. Primary tumors originate in the brain1, while secondary tumors spread from other body parts. Treatment options traditionally include surgery, radiation therapy, and chemotherapy. However, these approaches can be invasive and have severe side effects. The battle against brain tumors is being ...
Polyethylene glycol (PEG) derivatives have become pivotal in the pharmaceutical industry, revolutionizing drug delivery systems and enhancing the efficacy of various therapeutic agents. The unique properties of PEG derivatives, including their biocompatibility and ability to modify the solubility, stability, and bioavailability of drugs, make them indispensable in modern pharmacology. This ...
We recently spoke with Manuela Badiali, Rita Congiu, and Stefania Murru from the Laboratory of Genetics and Genomics, Microcitemico Pediatric Hospital – A. Cao, Cagliari, about how SOPHiA DDM™ RNAtarget Technology has helped them optimize their variant analysis workflow. ...
Alfa Cytology, a biotech company composed of scientists, bioinformatics, and oncologists, has recently announced its pancreatic cancer vaccine development services to provide further strategies for cancer therapy research. ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
Oncology drug development makes up almost half of the annual R&D expenditure of biopharmaceutical companies. Only 10% of drugs advanced to the clinical stage are successfully brought to market, with half of all failures attributed to lack of clinical efficacy. This means that approximately $60 billion dollars are spent annually on unsuccessful drugs.1,2 Contributing to these unchecked costs ...
This white paper details a study by Predictive Oncology and UPMC Magee-Womens Hospital. By combining the assets and domain expertise of both organizations, this collaboration aimed to improve ovarian cancer prognosis and treatment through accurate patient stratification and survival outcome predictions. Background and objective High grade serous carcinoma (HGSC) of the ovary is a complex and ...
Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system. Small molecule drugs ...
Alfa Cytology has announced tumor models customization service for pancreatic cancer research. Alfa Cytology, a biotech company specializing in cancer research, has recently unveiled the service on pancreatic cancer tumor model customization to dig into the generation and development of pancreatic cancer and correspondingly provides customized plans for study. Pancreatic cancer is one kind of ...